Market News & Trends
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate
VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc. recently announced the signing of a license agreement granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD).
PAREXEL Advances Patient-Centric Drug Development With Introduction of its Patient Innovation Center
PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access.
Sandoz & Teva Have Potential to Transform Epinephrine Injection Market
With no generic versions and few comparable alternatives, Mylan’s EpiPen has dominated the epinephrine injection device market for over a decade. However, this summer has…
Inoviem Scientific Enters Into Service-Based Partnership With XoNovo
Inoviem Scientific recently announced a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial…
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial
Opiant Pharmaceuticals, Inc. recently announced it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for the treatment…
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial
Pieris Pharmaceuticals, Inc. recently announced it has dosed the first patient in the company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology…
MilliporeSigma Launches Next-Generation Process Technologies for Intensified Drug Production
MilliporeSigma recently launched three new products to help biomanufacturers navigate the evolving biopharma landscape with increased speed, greater flexibility, and enhanced quality. These next-generation process…
Aucta Pharmaceuticals Signs Commercial Manufacturing Agreement With Catalent
Catalent Pharma Solutions recently announced a commercial supply agreement for Aucta Pharmaceuticals, Inc.’s (Aucta) vigabatrin. The agreement follows a successful development program to formulate vigabatrin…
Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca
Biothera Pharmaceuticals, Inc. recently announced a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.
Metrion Biosciences & AMRI Collaborate to Offer Ion Channel Drug Discovery Services
Metrion Biosciences Limited and AMRI recently announced they have signed a new collaboration agreement. The alliance will promote Metrion’s electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients.
CURE Pharmaceutical Expands Distribution of CUREfilm Technology With First Licensing Agreement
CURE Pharmaceutical recently announced it entered into a multi-year licensing agreement for the first time with a leading international cannabis company.
Reata Announces Receipt of $30-Million Milestone Payment
Reata Pharmaceuticals, Inc. recently announced it has received a $30-million milestone payment from its licensee, Kyowa Hakko Kirin Co., Ltd. following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan.
Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide
Novo Nordisk A/S recently announced the headline results from PIONEER 5, a Phase 3a trial with oral semaglutide in adults with type 2 diabetes and…
Ajinomoto Althea Celebrates 20 Years in San Diego & Opening of New Facility
Ajinomoto Althea, Inc., a leading contract development and manufacturing organization, celebrated its 20th year in operation, making it one of the true anchors of the…
Gerresheimer Gx Solutions Developing Packaging Solutions for Complex Injectable Drugs of Tomorrow
New sophisticated and sensitive injectable drugs require a new generation of custom-tailored pharmaceutical primary packaging. Gerresheimer is combining its expertise into a specialized team called…
UPM Pharmaceuticals Appoints New Director of Analytical Development
UPM Pharmaceuticals, a Contract Development and Manufacturing Organization (CDMO) focused on oral solid and semi-solid drug dosage forms, has appointed Dr. Chi-Chang Wung to the…
Global Contract Research Organization Announces $7.8-Million Extension Agreement
A major full-service, global contract research organization (CRO) has expanded its existing partnership with OmniComm Systems, Inc., a leading global provider of clinical data management technology.…
Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy
Adverum Biotechnologies, Inc. recently announced its Investigational New Drug (IND) application is active for the planned multi-center, open-label, Phase 1, dose-escalation study of ADVM-022, a…
SunGen Pharma Establishes Injectable Division, Forms Manufacturing Relationship
SunGen Pharma recently announced it has entered into a Manufacturing Agreement with Grand River Aseptic Manufacturing (GRAM) to manufacture generic injectable pharmaceutical products.
Cynata’s Stem Cell Therapy Meets All Safety & Efficacy Endpoints in Trial
Australian stem cell and regenerative medicine company Cynata Therapeutics Limited recently announced that CYP-001, its lead Cymerus mesenchymal stem cell (MSC) product candidate, met all clinical endpoints in a Phase 1 trial for the treatment of steroid-resistant acute graft-versus-host disease (GvHD).
